Skip Navigation


Carcinogenesis Advance Access originally published online on March 10, 2005
Carcinogenesis 2005 26(7):1224-1232; doi:10.1093/carcin/bgi066
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Material
Right arrow All Versions of this Article:
26/7/1224    most recent
bgi066v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (39)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bloethner, S.
Right arrow Articles by Kumar, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloethner, S.
Right arrow Articles by Kumar, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.26 no.7 © Oxford University Press 2005; all rights reserved.

Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines

Sandra Bloethner 1, Bowang Chen 1, Kari Hemminki 1, 2, Jan Müller-Berghaus 3, Selma Ugurel 3, Dirk Schadendorf 3 and Rajiv Kumar 1, 2, *

1 Division of Molecular Genetic Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 580, 69120 Heidelberg, Germany, 2 Department of Biosciences, Karolinska Institute, 141 57 Huddinge, Sweden and 3 Skin Cancer Unit, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

* To whom correspondence should be addressed. Tel: +49 6221 42 1806; Fax: +49 6221 42 1810; Email: r.kumar{at}dkfz.de

We studied global gene expression in three melanoma cell lines with the most common and potent V600E mutation in the B-RAF gene—four cell lines with a common Q61R mutation in the N-RAS gene and three cell lines with no mutations using human HG-U133A 2.0 micro-arrays with 22 277 transcripts. Data analysis using stringent criteria revealed several upregulated and downregulated genes in cell lines with B-RAF and N-RAS mutations compared with cell lines without mutations. We found 29 genes specifically upregulated and 32 genes downregulated in cell lines with B-RAF mutations, whereas 70 genes were upregulated and 39 downregulated in cell lines with N-RAS mutations; 11 genes showed overlapping upregulation and 45 downregulation. The micro-array data for nine selected genes were validated by the real-time PCR technique. Expression of a large number of genes, that encode members or regulators of the RAS/RAF/MEK/ERK pathways or are involved in metastasis or invasion, was affected in cell lines with mutations in B-RAF and N-RAS. Upregulated genes in cell lines with mutations included dual-specificity phosphatase 6 (DUSP6), sprouty 2 (SPRY2), v-akt murine thymoma viral oncogene homolog 3 (AKT3) and matrix metalloproteinase 14 (MMP14); downregulated genes included interleukin 18 (IL18), Krüppel-like factor 5 (KLF5) and inhibitor of DNA binding 2 (ID2). Our results, though carried on cell lines, provide a novel insight into the effect of mutations in the B-RAF and N-RAS genes on global gene expression in melanoma and highlight the complexity of mechanisms involved in tumour initiation and maintenance.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
G. Schaaf, M. Hamdi, D. Zwijnenburg, A. Lakeman, D. Geerts, R. Versteeg, and M. Kool
Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS Gene
Cancer Res., January 15, 2010; 70(2): 762 - 771.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Edwin, K. Anderson, and T. B. Patel
HECT Domain-containing E3 Ubiquitin Ligase Nedd4 Interacts with and Ubiquitinates Sprouty2
J. Biol. Chem., January 1, 2010; 285(1): 255 - 264.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
F. Edwin, K. Anderson, C. Ying, and T. B. Patel
Intermolecular Interactions of Sprouty Proteins and Their Implications in Development and Disease
Mol. Pharmacol., October 1, 2009; 76(4): 679 - 691.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. C. Brady, M. L. Coleman, J. Munro, S. M. Feller, N. A. Morrice, and M. F. Olson
Sprouty2 Association with B-Raf Is Regulated by Phosphorylation and Kinase Conformation
Cancer Res., September 1, 2009; 69(17): 6773 - 6781.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. A. Pratilas, B. S. Taylor, Q. Ye, A. Viale, C. Sander, D. B. Solit, and N. Rosen
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
PNAS, March 17, 2009; 106(11): 4519 - 4524.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. S. Anglesio, J. M. Arnold, J. George, A. V. Tinker, R. Tothill, N. Waddell, L. Simms, B. Locandro, S. Fereday, N. Traficante, et al.
Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors
Mol. Cancer Res., November 1, 2008; 6(11): 1678 - 1690.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. Lito, B. D. Mets, S. Kleff, S. O'Reilly, V. M. Maher, and J. J. McCormick
Evidence That Sprouty 2 Is Necessary for Sarcoma Formation by H-Ras Oncogene-transformed Human Fibroblasts
J. Biol. Chem., January 25, 2008; 283(4): 2002 - 2009.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. B. Oliveira, N. Bidere, J. E. Niemela, L. Zheng, K. Sakai, C. P. Nix, R. L. Danner, J. Barb, P. J. Munson, J. M. Puck, et al.
NRAS mutation causes a human autoimmune lymphoproliferative syndrome
PNAS, May 22, 2007; 104(21): 8953 - 8958.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. M. Shields, N. E. Thomas, M. Cregger, A. J. Berger, M. Leslie, C. Torrice, H. Hao, S. Penland, J. Arbiser, G. Scott, et al.
Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma
Cancer Res., February 15, 2007; 67(4): 1502 - 1512.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
M. Kono, I. S. Dunn, P. J. Durda, D. Butera, L. B. Rose, T. J. Haggerty, E. M. Benson, and J. T. Kurnick
Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression
Mol. Cancer Res., October 1, 2006; 4(10): 779 - 792.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
S Fritzsche, M Kenzelmann, M J Hoffmann, M Muller, R Engers, H-J Grone, and W A Schulz
Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 839 - 849.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. D. Onken, J. P. Ehlers, L. A. Worley, J. Makita, Y. Yokota, and J. W. Harbour
Functional Gene Expression Analysis Uncovers Phenotypic Switch in Aggressive Uveal Melanomas.
Cancer Res., May 1, 2006; 66(9): 4602 - 4609.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. B. Ramnarain, S. Park, D. Y. Lee, K. J. Hatanpaa, S. O. Scoggin, H. Otu, T. A. Libermann, J. M. Raisanen, R. Ashfaq, E. T. Wong, et al.
Differential Gene Expression Analysis Reveals Generation of an Autocrine Loop by a Mutant Epidermal Growth Factor Receptor in Glioma Cells
Cancer Res., January 15, 2006; 66(2): 867 - 874.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.